What problem are we solving?

Current cancer diagnosis is slow and inefficient

Process of cancer diagnostics requires several days and multiple visits

High anxiety and negative patient experience

Lack of accurate and automated tools supporting clinicians in their decision-making process

There are no tools for cancer treatment optimization

There are no reliable biomarkers supporting disease prognosis and treatment optimization

For 1 life saved, there are 3 to 10 overtreated patients

Overtreatment of patients negatively affects quality of life and bears additional healthcare costs

This is a title

Cancer is a global problem. Today, there is a 20% chance that cancer will be diagnosed in the course of a lifetime. Therefore, regular screening and the consequent biopsy procedure when exhibiting suspicious lesions have meanwhile become standard of care for different cancer types like breast, lung, colon or skin. Nevertheless, the current cancer diagnosis process remains slow and inefficient. Centralized labs require complex infrastructures and have high workflow maintenance costs. Moreover, the agonizing wait verifying that the detected lesion is benign or malignant can take up to several weeks. This causes unnecessary and extreme anxiety for the patient. The fact that more than 70% of patients who undergo a biopsy of suspicious lesions have a benign condition does not make waiting any better.

This is a title

Another major issue in the current clinical workflow is a lack of accurate optimization tools for patients diagnosed with cancerous lesions. These tools would prevent under- or overtreatment and improve patient outcomes. In the area of breast cancer, for example, we currently count 3-10 overtreated patients for every patient life saved (Marmot et al., 2012).This has a massive impact on the patient’s quality of life due to the severe side effects accompanying the cancer treatment. In addition, there is a high cost burden for the entire health ecosystem.

Current cancer diagnosis is slow and inefficient

Process of cancer diagnostics requires several days and multiple visits

High anxiety and negative patient experience

Lack of accurate and automated tools supporting clinicians in their decision-making process

This is a title

Cancer is a global problem. Today, there is a 20% chance that cancer will be diagnosed in the course of a lifetime. Therefore, regular screening and the consequent biopsy procedure when exhibiting suspicious lesions have meanwhile become standard of care for different cancer types like breast, lung, colon or skin. Nevertheless, the current cancer diagnosis process remains slow and inefficient. Centralized labs require complex infrastructures and have high workflow maintenance costs. Moreover, the agonizing wait verifying that the detected lesion is benign or malignant can take up to several weeks. This causes unnecessary and extreme anxiety for the patient. The fact that more than 70% of patients who undergo a biopsy of suspicious lesions have a benign condition does not make waiting any better.

There are no tools for cancer treatment optimization

There are no reliable biomarkers supporting disease prognosis and treatment optimization

For 1 life saved, there are 3 to 10 overtreated patients

Overtreatment of patients negatively affects quality of life and bears additional healthcare costs

This is a title

Another major issue in the current clinical workflow is a lack of accurate optimization tools for patients diagnosed with cancerous lesions. These tools would prevent under- or overtreatment and improve patient outcomes. In the area of breast cancer, for example, we currently count 3-10 overtreated patients for every patient life saved (Marmot et al., 2012).This has a massive impact on the patient’s quality of life due to the severe side effects accompanying the cancer treatment. In addition, there is a high cost burden for the entire health ecosystem.

Our value proposition

Patients

We improve the individual patient journey by ensuring a quick diagnosis (under 3 h) followed by personalized therapy plans with less side effects.

Clinicians

ARTIDIS significantly optimizes the clinical process by providing bedside cancer diagnosis, faster patient stratification, and medical insights that allow for tailored treatment decisions.

Regulators

ARTIDIS approach grants patients access to state-of-the-art healthcare technology and efficient and effective treatment.

Payers

ARTIDIS optimizes the current clinical workflow and establishes a foundation of value-based healthcare by providing validated clinical parameters and minimizing overtreatment.

How do we change the status quo?

Current cancer diagnosis is slow and inefficient. There are no good tools for cancer treatment optimization. By combining device insights with data we personalize the patient journey.

Technology

Do you know how cancer builds metastases? ARTIDIS can predict the probability of a patient developing metastases.

ARTIDISTM is our nanomechanical sensor that captures the physical properties of tissue enabling the clinician to differentiate between benign and malignant tissue in under three hours. In addition, the technology allows the clinician to define the aggressiveness of the tumor with very high accuracy based on the nanomechanical signature of the cells. Only very soft cells can squeeze through all different tissues to create distant metastases that are responsible for more than 90% of cancer related deaths. The nano-probe measures the tissue’s physical properties allowing us to discover robust nano-mechanical biomarkers and predict disease development. Moreover, ARTIDIS technology is not limited to cancer and can analyze any living tissue.

graphic_technology

ARTIDISNet platform - more than a device

ARTIDISNet is an AI-powered algorithm integrating patient nanomechanical biomarkers and hundreds of relevant data points from the patient's own clinical data to provide the patient with personalized high-quality treatment. Together with clinical data like tumor size, lymph nodule status, etc. we integrate the nanomechanical biomarker data and combine them with imaging, genetic, and histopathology parameters, as well as therapy follow-up data to generate medical insights and support treatment decision-making. ARTIDISNet enables the clinician to provide the right patient with the right treatment and to maximize the positive treatment results.

graphic_dataplatform_left2_4
graphic_dataplatform_center

Our team

Board members

Management

Team

Recent news

Press

Key scientific publications

We're hiring!

You are looking for a job that will allow you to improve people’s lives? You believe in the power of innovation and nanotechnology? So do we at ARTIDIS. We are a passionate team of open-minded individuals driven by scientific curiosity, innovation, and the desire to make a positive impact for the patient and the healthcare ecosystem. If you want to become part of our journey, please contact us.

Keep in touch

If you want to become part of our journey, please contact us.



+41 61 633 29 94

Hochbergerstrasse 60c, 4057 Basel, Switzerland

info@artidis.com